Fresenius Medical Care Ag · XETR:FME
Fresenius Medical Care — Shareholder Meeting (May 2014)
15 slides from Fresenius Medical Care's shareholder meeting presentation, May 15, 2014
Slide 1: Annual General Meeting 2014 Welcome
Annual General Meeting 2014 Welcome Rice Powell Chief Executive Officer and Chairman of the Management Board Frankfurt | May 15, 2014
Slide 2: Agenda
Agenda 1. Introduction 2. Business Update 3. Share price / Dividend 4. Vision and Strategy for 2020
Slide 3: Record revenue and earnings for 2013
Record revenue and earnings for 2013 Revenue Net income +6% +6% Billion US$ Million US$ 14.6 1,110 CAGR CAGR 1,187 10% 13.8 13% 1,047 331 5.5 2003 2012 2013 2003 2012 2013 CAGR = Cummulative annual growth rate © | Annual General Meeting 2014 3
Slide 4: Fresenius Medical Care today
Fresenius Medical Care today $10.6bn Global $3.5bn Services Production Dialysis Revenue Network Products Revenue 3,250 ~40 Sites ~$500m Clinics Care Coordination 34% of 270,000 Dialysis 40.5m Patients Treatments Product Market © | Annual General Meeting 2014 4
Slide 5: Achieved guidance for fiscal year 2013
Achieved guidance for fiscal year 2013 FY 2013 Growth in $ millions in % Net Revenue 14,610 6 Earnings before interest and tax (EBIT) 2,256 2 Net income 1,110 (6)* / 6** Operating Cash Flow 2,035 * Reported ** 2012 adjusted for investment gain of US$ 140 million © | Annual General Meeting 2014 5
Slide 6: Revenue breakdown for fiscal year 2013
Revenue breakdown for fiscal year 2013 North America International ~ 34% of total revenue Revenue $ 9,606 m + 6% Revenue $ 4,970 m + 6%cc Organic growth + 4% Organic growth + 5% Europe $ 3,023 m + 3%cc Asia-Pacific $ 1,104 m + 8%cc Latin America $ 843 m + 15%cc 4 3 1 North America 66% 2 14,610 2 Eur
Slide 7: 2013 − 17th consecutive dividend increase
2013 − 17th consecutive dividend increase Dividend per +3% ordinary share in € 0.75 0.77 2013 Earnings after tax decline of 6% on a reported basis Increase in dividend despite earnings driven policy 0.17 1997 2012 2013 © | Annual General Meeting 2014 7
Slide 8: Delivering long-term value
Delivering long-term value Total Return 2003 to 2013 – Average annual performance Fresenius Medical Care in € 15% DAX-Index* 11% DJ Eurostoxx 8% Healthcare-Index 0% 4% 8% 12% 16% * no dividends or coupons © | Annual General Meeting 2014 8
Slide 9: 2014 Outlook
2014 Outlook 2013 2014 E In $ millions Reported Revenue 14,600 ~ 15,200 EBIT 2,256 ~ 2.2bn Net income 1,110 1.0–1.05bn Outlook excludes potential net cost savings from the global efficiency program for 2014 of up to 60 million US$ before tax Potential acquisitions are not included © | Annual Gen
Slide 10: Development of dialysis patient numbers
0 500.000 1.000.000 1.500.000 2.000.000 2.500.000 3.000.000 3.500.000 4.000.000 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 Source: 2013 Company data and estimates 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Slide 11: Our Vision of Care Coordination
Our Vision of Care Coordination Dialysis Vascular Services Primary Care In Patient Dialysis Products Lab Nephrology Pharmacy Post- Acute © | Annual General Meeting 2014 11
Slide 12: New targets for 2020
New targets for 2020 $28.0bn CAGR 18% 10% 2015 – 2020 Growth rates p.a. 20% $14.6bn 3% Revenue ~ 10% 24% 62% $4.2bn Net Income High Single Digit 73% 30% 70% 2000 2013 2020 Services Products Care Coordination CAGR = Cummulative annual growth rate © | Annual General Meeting 2014 12
Slide 13: Creating a future worth living. Thank you
CREATING A FUTURE WORTH LIVING. FOR DIALYSIS PATIENTS. WORLDWIDE. EVERY DAY. Thank you very much for your attention!13 © | Annual General Meeting 2014
Slide 14: Annual General Meeting 2014 Welcome
Annual General Meeting 2014 Welcome Rice Powell Chief Executive Officer and Chairman of the Management Board Frankfurt | May 15, 2014
Slide 15: Safe Harbor Statement
Safe Harbor Statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. The Company has based these forward-looking statements on its views w
Fresenius Medical Care — Shareholder Meeting (May 2014) on 6ix